Baseload Power U.S. appoints new president
STOCKHOLM, May 7, 2025 /PRNewswire/ -- Baseload Power U.S. (BPUS) is pleased to announce that Jesper Jolma has been named President of the company. He will be responsible for leading BPUS's work to expand development geothermal resources in the western United States.
Jesper has been a key member of Baseload Capital since 2018, where he played a key role in establishing Baseload Power Taiwan in 2019 and BPUS in 2020. He most recently served as Investment Manager for the U.S. at Baseload Capital, during which time he was instrumental in closing Baseload's Series B funding round.
With a strong educational background and a breadth of experience in geothermal energy investment and project development, Jesper is dedicated to advancing innovative renewable energy solutions and scaling up geothermal projects globally. Jesper Jolma holds an Executive MBA-equivalent from Harvard Business School and a Master of Science in Industrial Engineering and Management.
Jesper commented "I am thrilled to continue my career with Baseload and to move into this new role at Baseload Power U.S. Our strategy of developing geothermal projects through partnerships and collaboration is a great fit for the constantly evolving geothermal ecosystem in the U.S. I am looking forward to working with colleagues here and abroad to push projects forward and advance the geothermal industry."
Baseload Capital COO Pernilla Wihlborg noted "It has been a privilege to watch Jesper grow into a leader through his tenure at Baseload Capital. We are confident in his continued success in developing our U.S. and global business."
Baseload Capital CEO Alexander Helling added "Jesper has been integral to the development of Baseload Capital thus far and we are thrilled that he will continue to contribute to our mission of scaling geothermal energy worldwide by leading Baseload Power US."
CONTACT:
For more information, please contact:
Kristina Hagström-Ilievska CMO, Baseload Capital
kristina.hagstrom.ilievska@baseloadcap.com
Tel: +46 (0) 732330039
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/baseload-capital-sweden-ab/r/baseload-power-u-s--appoints-new-president,c4147087
The following files are available for download:
https://news.cision.com/baseload-capital-sweden-ab/i/jesper-pressrelease3,c3406885
jesper pressrelease3
https://news.cision.com/baseload-capital-sweden-ab/i/jesper-pressrelease1,c3406887
jesper pressrelease1
Cision
View original content:https://www.prnewswire.com/news-releases/baseload-power-us-appoints-new-president-302448959.html
SOURCE Baseload Capital Sweden AB
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 hours ago
- Business Wire
Chris Cope Joins CADDi as Vice President of Engineering
CHICAGO & TOKYO--(BUSINESS WIRE)-- CADDi, the AI-powered data platform transforming manufacturing by democratizing supply chain and design data, today announced the appointment of Chris Cope as Vice President of Engineering. Cope brings over 20 years of expertise in building technology with a strong focus on artificial intelligence, security, and automation. "There is no company better positioned (than CADDi) to deliver AI-driven transformation to the world's manufacturers for the years to come. " Share Before joining CADDi, Cope held critical leadership roles at high-growth technology companies including Xometry and Aledade. At Xometry, he served as Senior Director of Software Engineering and Chief Information Security Officer (CISO), playing an instrumental role in scaling the world's largest AI-driven manufacturing marketplace from its Series B funding round through IPO. Cope successfully led software development and site-reliability teams, ensuring stringent compliance and security requirements essential for Aerospace and Defense customers. At Aledade, an innovative AI-enabled healthtech startup, Cope led DevOps and Security initiatives, driving the implementation of secure, scalable systems that supported rapid growth. 'I have admired CADDi for a long time," said Cope. "There is no company better positioned to deliver AI-driven transformation to the world's manufacturers for the years to come. I look forward to accelerating our technological capabilities and further cementing CADDi's position as a global leader in manufacturing technology.' With Cope's appointment, CADDi strengthens its commitment to scaling its engineering operations, enhancing security, and leveraging automation to maintain the highest standards demanded by leading manufacturers worldwide. 'Chris's track record in hyper-growth environments and his deep expertise in AI and secure platform development make him an ideal fit for CADDi as we continue our rapid expansion,' said Yushiro Kato, CEO and Co-Founder of CADDi. 'His strategic insights and obsessive focus on automation will help propel our engineering team forward, enhancing our platform's value to our global customer base.' About CADDi CADDi is an AI-powered data platform transforming manufacturing by making design and supply chain data accessible, insightful, and actionable. Founded in 2017 by industry veterans Yushiro Kato (McKinsey) and Aki Kobashi (Apple, Lockheed Martin), CADDi converts decades of scattered and unstructured manufacturing data into actionable intelligence, driving efficiency, reducing costs, and accelerating innovation across manufacturers globally. Headquartered between Tokyo and Chicago, CADDi has operations in Japan, the United States, Vietnam, and Thailand. CADDi supports key sectors including automotive, medtech, biotech, robotics, industrial machining, industrial electronics, and prototyping. Recognized for innovation, CADDi was named to Fast Company's Most Innovative Companies list in 2024 and won the 2024 SaaS Award for Best Business Intelligence and Engineering Management Software. For more information, visit Additional Resources:
Business Wire
2 days ago
- Business Wire
Mitiga Strengthens Executive Leadership Team with Appointment of Chief Marketing Officer and Chief Financial Officer
NEW YORK--(BUSINESS WIRE)--Mitiga, the real-time Cloud Detection and Response (CDR) solution for enterprises, today announced that it has appointed John Vecchi as chief marketing officer and John Stockel as chief financial officer. These key hires bring decades of experience in cybersecurity and high-growth tech environments, underscoring Mitiga's commitment to scaling its operations, expanding its market reach, and solidifying its position as a critical partner for organizations navigating complex cloud security challenges. Vecchi brings significant experience driving enterprise security and technology solutions to market. He has held multiple CMO and executive leadership roles across cybersecurity companies, including Phosphorus Cybersecurity, Solera Networks, Zscaler, Anonyome Labs, Blue Coat, Check Point Software, and McAfee. His expertise spans global marketing strategy, brand development, and product innovation. Stockel joins Mitiga from Deepwatch, where he played a key role in scaling the company from an early-stage startup to a leading Managed Detection and Response (MDR) provider. His extensive background spans finance, operations, and corporate development at fast-scaling cybersecurity and technology firms. He also brings investor-side expertise from his time at ABS Capital, where he focused on companies in IT infrastructure and cybersecurity, including GuidePoint Security. As CFO, Stockel will oversee Mitiga's finance, legal, and corporate development functions, helping drive the company's next phase of hyper-growth. Vecchi, as CMO, will lead global marketing and brand strategy, demand generation, and communications, helping to expand Mitiga's presence and reach across enterprise security markets. Together, they will help scale Mitiga's impact, addressing the rapidly evolving threats that span multi-cloud environments, SaaS applications, and related human and non-human identities. 'This is a pivotal time for Mitiga, and I'm excited to build on the company's momentum and deliver financial strategies to support Mitiga's strategic objectives and align our resources to continue our innovation and market expansion,' said Stockel. 'The cybersecurity space is evolving quickly, and Mitiga is at the forefront with a unique and differentiated solution.' 'I've spent my career bringing innovative cybersecurity technologies to market, and Mitiga's platform is among the most exciting I've seen,' Vecchi says. 'It's a rare chance to help shape a category-defining solution at a time of massive cloud transformation, and I'm thrilled to be a part of it.' These appointments come on the heels of significant expansion for Mitiga, including the early 2025 addition of Charlie Thomas as chief executive officer and the company's recent $30 million Series B funding round led by SYN Ventures. 'Expanding our executive team with seasoned leaders like John Stockel and John Vecchi is a critical step as we scale,' said Thomas. 'Their experience in growth stage tech and cybersecurity will help Mitiga meet the moment as demand for cloud-native threat response and readiness continues to grow.' For more information about Mitiga, visit About Mitiga Mitiga is the industry's most complete solution for SaaS and Cloud Detection and Response (CDR): built by investigators, for investigators. We deliver the modern capabilities that enterprises have been missing, equipping SOC teams with panoramic visibility across clouds, identities, and SaaS, automation that speeds investigations, and rich context that informs cloud threat detection, hunting, and incident response. With Mitiga's platform, security teams can zero in on modern threats at cloud speed and scale, uncovering what other solutions miss, to minimize impact and maximize resiliency.
Yahoo
27-05-2025
- Yahoo
GlycoEra raises $130M, riding interest in protein degraders
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A biotechnology startup developing drugs designed to eliminate troublesome proteins found outside of cells has raised $130 million to start its first clinical trial. The startup, GlycoEra, will use the Series B funds to generate initial clinical data for its lead program, an immune disease treatment dubbed GE8820. It intends to bring a second immune drug into human testing as well. GlycoEra views GE8820 as having the type of broad potential that could make it a 'pipeline in a product,' said company president and CEO Ganesh Kaundinya. The drug targets IgG4, a circulating antibody that can be protective against allergies, but malfunctions and attacks the body's own tissues in many autoimmune conditions, among them the skin disorder pemphigus and the kidney condition primary membranous nephropathy. GE8820 is a dual-acting drug that coaxes the body into destroying this defective IgG4. One part of the molecule binds to the antibody and drags it to the liver. The other part then latches onto a receptor that absorbs IgG4 into cells, where it's trashed by an internal protein-disposal system. According to GlycoEra, preclinical testing has shown the approach can remove malfunctioning IgG4 antibodies with the type of precision not seen with other approaches. By doing so, GE8820 may avoid the broadly immunosuppressive effects of other autoimmune medicines. It may also ease the 'burden on the healthcare system,' Kaundinya said. Patients typically 'get treated, they get better, they are fine, and then they come back to that relapse,' Kaundinya said. 'Our approach not only enables the patients to live better lives, it also overall contributes to better healthcare economics across the board.' GlycoEra has publicly disclosed three other programs behind GE8820, but hasn't specified which diseases they're targeting. The company could submit a request to begin trials for its second drug in 2026, according to its website. Novo Holdings led GlycoEra's Series B round, which involved the venture arms of Roche and Bristol Myers Squibb, Sofinnova Partners and several other firms. 'What really stood out with GlycoEra is that you had a use case here where, in autoimmune disease, there's limited competition, a high amount of medical need and the biological rationale is really strong,' said Novo Holdings partner Max Klement. 'As we see the autoimmune disease space evolve, precision medicine makers such as GlycoEra are going to come to the forefront.' GlycoEra is named after glycosylation, the process by which sugar chains are attached to proteins. The company is headquartered in Wädenswil, Switzerland and has a U.S. footprint in Newton, Massachusetts. It was spun out of Swiss biotech LimmaTech Biologics in January 2021, and raised approximately $49 million in Series A funding that November. The company's latest round is further evidence of continued interest in so-called protein degraders, which offer a way of getting to proteins traditional drugmaking methods can't reach. Research into protein degradation has taken off since the turn of the century, yielding an array of companies using different methods to destroy harmful proteins. Many of these companies are focused on protein targets inside of cells. GlycoEra is among those zeroing in on so-called extracellular proteins outside of cells or on their membranes. Fellow startups EpiBiologics and Lycia Therapeutics are as well. Sign in to access your portfolio
